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Abstract
Background:  Traditionally, tumors have been classified by their morphologic appearances.
Unfortunately, tumors with similar histologic features often follow different clinical courses or
respond differently to chemotherapy. Limitations in the clinical utility of morphology-based tumor
classifications have prompted a search for a new tumor classification based on molecular analysis.
Gene expression array data and proteomic data from tumor samples will provide complex data that
is unobtainable from morphologic examination alone. The growing question facing cancer
researchers is, "How can we successfully integrate the molecular, morphologic and clinical
characteristics of human cancer to produce a helpful tumor classification?"
Discussion: Current efforts to classify cancers based on molecular features ignore lessons learned
from millennia of experience in biological classification. A tumor classification must include every
type of tumor and must provide a unique place for each tumor within the classification. Groups
within a classification inherit the properties of their ancestors and impart properties to their
descendants. A classification was prepared grouping tumors according to their histogenetic
development. The classification is simple (reducing the complexity of information received from the
molecular analysis of tumors), comprehensive (providing a place for every tumor of man), and
consistent with recent attempts to characterize tumors by cytogenetic and molecular features. The
clinical and research value of this historical approach to tumor classification is discussed.
Summary: This manuscript reviews tumor classification and provides a new and comprehensive
classification for neoplasia that preserves traditional nomenclature while incorporating information
derived from the molecular analysis of tumors. The classification is provided as an open access XML
document that can be used by cancer researchers to relate tumor classes with heterogeneous
experimental and clinical tumor databases.
Background
Challenge: creating a molecular classification of cancer
In January 1999, the U.S. National Cancer Institute (NCI)
issued a challenge to the scientific community "to harness
the power of comprehensive molecular analysis technolo-
gies to make the classification of tumors vastly more
informative. This challenge is intended to lay the ground-
work for changing the basis of tumor classification from
morphological to molecular characteristics." [1] Not sur-
prisingly, this has resulted in lively debate over the relative
value of morphologic and molecular classifications[2].
What is a tumor classification?
A classification is an organization of everything in a
domain by hierarchical groups, according to features gen-
eralizable to the members of the groups. Four terms with
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distinctly different meanings have been used interchange-
ably with "classification," leading to considerable confu-
sion among pathologists and cancer researchers. These
terms are: identification, discrimination, taxonomy, and
ontology [3]. Identification (also known as diagnosing or
naming) is the act of placing something into its correct
slot within an existing classification. Discrimination is
finding features that separate members of a group accord-
ing to expected variations in group behavior. Examples of
discrimination are "grading and staging." Grading and
staging involve reporting additional morphologic features
(grading) or clinical behavior (staging) that help predict a
particular tumor's clinical course or response to therapy. A
taxonomy is a complete listing of all the members of a
classification. In the case of neoplasia, a taxonomy would
be the complete listing of all the different named tumors.
An ontology is a rule-based grouping of some portion of
a taxonomy. Ontologies support queries and logical infer-
ences pertaining to the [ontologic] group members.
Much of the current work in the molecular classification
of tumors is actually discriminant analysis disguised as
classification. In a typical gene expression array study, the
researcher will look at a group of tumors of a specific type.
Cluster analysis of the gene expression array values will
help separate the tumors into groups with common
expression patterns. Some of these groupings will prove to
have a specific biologic feature (e.g. increased tendency to
metastasize, higher response to a chemotherapeutic agent,
lengthened survival) [4-8]. The groupings seldom qualify
as new classes if they merely represent variations in the
expected biology of a type of tumor. Variant groups are
disqualified as classes if it can be shown that a tumor of a
certain type may progress from one variant group to
another variant group over time (e.g. slow-growing vari-
ant at one stage in development and fast-growing variant
at another stage). A key concept in a classification is that
the members of one class cannot transform into the mem-
bers of another class (i.e. a colon carcinoma does not
transform into a colon lymphoma).
In the author's opinion, common misuses of the term
"classification" form the greatest impediment to progress
in the field of cancer genetics. It is impossible to create a
molecular classification of tumors based solely on the sep-
aration of tumors by variations of molecular markers.
Clustering by variation only identifies differences among
tumors and is not sufficient to establish a classification.
Classification is the process of showing that certain differ-
ences reliably distinguish the members of a group from
the members of all other groups, and that these differ-
ences apply to the group's hierarchical descendants.
Therefore, the data that comes from the molecular analy-
sis of tumors can be considered a first-step in the process
of tumor classification.
Who actually uses tumor classifications? The author con-
siders himself an example of someone who needs to have
a comprehensive tumor classification. As Program Direc-
tor for Pathology Informatics within the National Cancer
Institute's (NCI's) Cancer Diagnosis Program, I am
responsible for developing research initiatives that assem-
ble and organize large amounts of pathology data. These
efforts need to interoperate with other NCI programs,
including the NCI Center for Bioinformatics, which has
created tools for linking experimental data, pathology
data and clinical trial data. A tumor classification serves as
the "key" data structure that links the names of tumors to
tumor-related data held in NCI's different clinical and
experimental databases. A good classification should help
drive-down the complexity of enormous databases and
help us discover relationships among different data ele-
ments by assembling data under sensible group hierar-
chies.
The importance of tumor classification
Classifications are important because class properties are
shared among the members of a class, and because mem-
bers of a class inherit the properties of their ancestors.
Simply knowing the class of a bacteria can provide a
microbiologist with deep insights relating to the expected
growth conditions for the organism and the types of anti-
biotics that may be effective against the organism.
A classification can be thought of as the encapsulation of
all knowledge related to a domain. In a modern classifica-
tion, the elements of the classification (classes and
instances) serve as annotation keys and are capable of
relating all data to the classification, regardless of the loca-
tion of the data. Using classed tumor names [from a
standard nomenclature], a search of gene expression array
databases might locate gene array data specific to the class.
In the last few years, efforts have begun to characterize
tumors based on molecular pathways that will serve as tar-
gets for new, non-toxic chemotherapeutic agents. There
have been early successes with tumors sensitive to the
inhibition of tyrosine kinases (gastrointestinal stromal
tumors (GIST) and chronic myelogenous leukemia) with
Gleevec [9]. Both these tumors derive from non-endoder-
mal/ectodermal embryonic layers, suggesting that molec-
ular pathways (hence targets for chemotherapy) may be
class-dependent.
Current status of tumor classification
At present, there is simply no comprehensive modern
tumor classification. A practical, though disappointing
explanation for this situation is offered by Diamandopou-
los. "Since there are almost limitless varieties of tumors, a
complete table of classification would require many
pages. Any shortened version is not only necessarilyBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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incomplete but also likely to be confusing."[10] This dour
perspective may actually represent the modern patholo-
gist's perspective. Current tumor classifications suffer
from the following:
1. Classifications are created piecemeal for specific sites or
organ systems. Nobody has published a comprehensive
classification, although comprehensive taxonomies have
been attempted.
2. Classifications are often based on medical disciplines,
rather than on any biologic principles (e.g. classification
of dermatologic tumors).
3. A given tumor will appear redundantly when subclassi-
fications are merged.
4. No tumor classification has been prepared in a standard
format designed to exchange, merge or analyze heteroge-
neous biological data
The most widely-used authoritative resources are the
World Health Organisation classifications, which list the
tumors that occur at different body sites [11]. The prob-
lem with an organ system approach to classification is that
every organ contains organ-specific and organ non-spe-
cific cell types. The brain, for instance, contains connec-
tive tissue and lymphoid tissue, and therefore is prone to
tumors of connective tissue and lymphoid tissue. A listing
of tumors that occur in the brain must include: osteocar-
tilaginous tumors, lipoma, fibrous histiocytoma, heman-
giopericytoma, rhabdomyosarcoma, melanoma,
lymphoma and myeloma, among others. These same
tumors will be included again and again in every site-spe-
cific classification. Although each term may occur only
once in each site-specific classification, the same lesion
may occur a virtually limitless number of times when the
site classifications are combined into a comprehensive
classification of tumors.
Although cancer taxonomies are different from classifica-
tions, they usefully provide all the instances of tumors
that must be grouped within a classification. Excellent
tumor taxonomies are now publicly available at no cost.
Unified Medical Language System (UMLS) Metathesaurus
The UMLS Metathesaurus is a collection of medical terms
collected from about 100 different nomenclatures. It is
the richest source of term synonymy in existence and has
a comprehensive and detailed set of neoplasia-related
terms. The UMLS Metathesaurus is available from the U.S.
National Library of Medicine at: http://www.nlm.nih.gov/
research/umls/
Medical Subject Headings (MESH)
MESH is a curated hierarchical listing of medical terms
and includes a detailed and comprehensive tumor
nomenclature. MESH is provided by the U.S. National
Library of Medicine at: http://www.nlm.nih.gov/mesh/
filelist.html
International Classification of Diseases-Oncology (ICD-O)
The ICD-O is prepared by the World Health Organization.
It is in its third version and is available at no cost in the
U.S. via state central cancer registries. Non-U.S. facilities
should contact their health services for information. Addi-
tional information can be obtained at the NCI's Surveil-
lance Epidemiology and End Results (SEER) website at:
http://training.seer.cancer.gov/module_icdo3/
icdo3_home.html
NCI-Thesaurus
The National Cancer Institute curates a collection of terms
related to cancer. The thesaurus can be freely downloaded
from: ftp://ftp1.nci.nih.gov/pub/cacore/EVS/
Methods
The general rules for classification can be summarized:
1. A classification is a hierarchical grouping, with each
group defined by the greatest number of taxa (informative
features) that can apply to every instance of the group
2. Every instance must fit into the classification, and every
instance and group must have exactly one slot in the clas-
sification.
3. Instances and groups are separable from other instances
and groups by taxa.
4. Every classification must be constantly tested and
restructured (groups and instances) as needed
The classification offered in this article is based on devel-
opmental histogenesis and is very similar to classifications
described in the mid 1950s [12]. The reasons for this
approach to tumor classification are:
1. Organs may have multiple embryologic derivatives (e.g.
skin contains tissues of ectodermal, neuroectodermal and
mesodermal lineages), but any given cell has only one lin-
eage. This means that a histogenetic classification can
assign any tumor to a unique position within the classifi-
cation.
2. For the most part, tumors have a cell developmental
stage. For instance, blastomas are thought to arise from a
cell type that precedes organ differentiation. Squamous
cell carcinomas of skin are tumors that have features ofBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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cell type that developed from one of the embryonic layers
(ectoderm). An embryologic approach permits us to
assign a cell type and a developmental stage to tumors.
3. A classification based on developmental histogenesis is
relevant to the behavior of tumors. Ectoderm and endo-
derm-derived tumors metastasize via lymphatics. Mesen-
chyme-derived tumors tend to metastasize by
hematogenous spread.
4. A classification based on develomental histogenesis is
consistent with modern molecular analysis of tumors.
Mesenchyme-derived tumors tend to be characterized by
simple fusion genes. Ectoderm and endoderm-derived
tumors tend to be genetically unstable and cannot be
characterized by a single genetic abnormality. Primitive
blastomas share similar markers regardless of the organ of
origin.
Results
The classification schema
The complete classification is available as a supplemental
XML file with this article. An abbreviated classification,
containing developmental divisions, is shown below. The
complete classification schema is available as an anno-
tated XML document with this article [see Additional file
1].
embryonic
primitive
 primitive_differentiating
 totipotent_or_multipotent_differentiating
 limited_differentiating
 germ cell
 primitive_non_differentiating
non_primitive
 endoderm_or_ectoderm
 endoderm_or_ectoderm_surface
 endoderm_or_ectoderm_endocrine
 endoderm_or_ectoderm_parenchymal
 odontogenic_epithelium
 mesoderm
 mesenchyme
 connective_tissue
 muscle
 fibrous_tissue
 vascular
 adipose_tissue
 bone_cartilage
 heme_lymphoid
 non_mesenchymal_mesoderm
 coelomic
 coelomic_ductal
 coelomic_cavities
 coelomic_gonadal
 sub_coelomic
 sub_coelomic_gonadal
 sub_coelomic_endocrine
 sub_coelomic_ nephric
 neuroectoderm_neural_plate
 neural_tube
 neural_tube_parenchyma
 neural_tube_lining
 neural_crest
 peripheral_nervous_system
 neural_crest_endocrine
 neural_crest_melanocytic
Explanation of the classification
The classification assigns tumors to the different stages in
human development, ignoring embryologic categories
that are not associated with tumors and combiningBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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embryologic categories that do not serve to distinguish
tumors of a given type.
The first division of the classification divides tumors as
embryonic (from which the body develops) or trophob-
lastic (extra-embryonic) lineage. From the embryonic
class come the primitive cells (also call totipotent cells)
that precede the differentiated cells. The primitive cells
give rise to several subclasses of tumors
• Primitive tumors that remain uncommitted. This would
include the Ewing family of tumors, which includes
Ewing's tumor peripheral neuroectodermal tumors
(PNET), and intra-abdominal desmoplastic small-round-
cell tumor [13]. The tumor cells may show certain features
of differentiation, but the cells are not equivalent to any
specific differentiated cell-type, and seem to occupy a
primitive developmental state that precedes the develop-
ment of embryonic layers.
• Germ cell
• Primitive tumors that differentiate. This group can be
divided into primitive tumors with multi-lineage differen-
tation (as in teratomas) and primitive tumors with
restricted differentiation (less than three embryonic lay-
ers, such as pancreatoblastoma and hepatoblastoma).
The concepts of germ cells and germinal cells are often
confusing to pathologists, who use these terms somewhat
differently than embryologists. For pathologists, germ
cells are the specialized cells that give rise to ova (in the
female) and sperm (in the male). The process of differen-
tiation of ova and sperm is no different than the process
of differentiation for any other cell type, and the most fre-
quently occurring tumors in this lineage are dysgermino-
mas (in females) and seminomas (in males). Germ cells
are differentiated cells and should not be classified with
totipotent, primordial, uncommitted or primitive cells.
The term germinal cells is probably best avoided alto-
gether. It is sometimes used to mean totipotent, some-
times as a synonym for germ cells and sometimes to
indicate lineage from one of the early germ layers. All
three meanings are unrelated, and the term "germinal" is
confusing when applied to tumor classification. In the
classification, "germ cell" is intended to mean only one
thing: the cell lineage that gives rise to differentiated ova
or sperm.
In the classification, the class of endodermal and ectoder-
mal derived tumors are combined. This is done simply
because there seems to be no biologic, clinical, morpho-
logic, or molecular differences among the tumors derived
from either of these germ layers. This division contains
most of the commonly occurring tumors of man. Among
the tumors of the endoderm/ectoderm division, there
may be some value in subdividing these by functional cell
type. The classification separates the epithelial tumors
that arise from ectoderm/endoderm surface epithelium
(which would include squamous cell carcinoma of skin or
bronchus or esophagus, and adenocarcinoma of colon)
from tumors that arise from the ectodermal/endodermal
organ epithelium (breast carcinoma, salivary gland carci-
noma, pancreatic carcinoma, hepatocellular carcinoma)
and tumors arising from ectoderm/endoderm endocrine
epithelium (thyroid papillary and follicular carcinoma
and pituitary adenoma).
The class of mesodermal tumors is particularly confusing
to the non-embryologist because it contains all sarcomas,
as well as tumors derived from specialized mesodermal
epithelium. In human development, the mesoderm is the
embryonic layer separating the ectoderm and the endo-
derm. It gives rise to all of the connective tissue of the
body (i.e. the mesenchyme). The mesenchymal tissues are
usually divided into the soft tissues (deriving from mus-
cle, fibrous tissue, and vascular tissue), hard tissue (i.e.
bone and cartilage lesions) and hematopoietic (which
would include all lymphomas and leukemias regardless of
their tissue of origin). In addition to the mesenchyme, the
mesoderm is capable of creating lumen or cavities lined
by specialized mesodermal epithelium. The coelomic cav-
ities become the pleura, peritoneum, pericardium, and
joint spaces, lined by mesothelium and synovium. These
give rise to mesothelioma and to synovial sarcoma, two
tumors that are morphologically similar, composed of
both epithelial cells and spindle cells.
A very specialized coelomic lining cell covers the gonads.
These cells are morphologically, clinically and genetically
distinct from the other coelomic lining cells and are
assigned their own subclass, which includes papillary
serous carcinoma of ovary.
The coelom is also capable of forming epithelial-lined
ducts. These ducts (such as the paramesonephric duct)
give rise to the Fallopian tubes and uterus. All uterine and
cervical cancer fall in the class of mesodermal, coelomic-
ductal tumors. The mesodermal lineage of these tumors is
consistent with the variety of mixed epithelial and non-
epithelial tumors arising from the uterus (endometrial
carcinoma, carcinosarcoma of endometrium, heterolo-
gous mixed mesodermal tumors of uterus).
A specialized mesoderm develops subjacent to coelomic
cavities. Specialized sub-coelomic mesoderm tissues give
rise to the gonads, the adrenal cortex and to the kidneys.
Tumors derived from these specialized mesodermal tis-
sues are assigned their own subclasses. The mesoderm
that develops as gonadal stroma gives rise to the sex cord-BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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stromal tumors of the ovary and testis (e.g. granulosa cell
tumor, thecal tumors, Sertoli-Leydig tumors, sex cord
tumor with annular tubules). The mesoderm that devel-
ops as adrenal cortex gives rise to cortical adenomas and
carcinomas. The mesoderm that develops as kidney gives
rise to renal cell carcinoma and all of its variants.
Cells deriving from neuroectoderm account for brain
tumors (neural tube) and tumors derived from the neural
crest (peripheral nervuous system tumors, some neuroen-
docrine tumors and melanocytic tumors). True blastic
brain tumors (tumors derived from cells that have not
demonstrated neuroectodermal differentiation) would
not be classified among tumors deriving from neuroecto-
derm (e.g. medulloblastoma). Not every tumor with a
blastoma suffix is derived from primitive cells. Some blas-
tomas are highly anaplastic versions of tumors that derive
from differentiated cells. Glioblastoma is a good example.
These tumors are closely related to high grade astrocyto-
mas, and they would be classed as tumors of neural tube
parenchyma.
Features of the tumor classification
1. Each tumor occurs only once in the classification
2. The classification is comprehensive (e.g. every tumor of
man can be placed somewhere within the classification.
3. The classification is simple. One of the purposes of a
classification is to drive down the complexity that exists
when the domain taxonomy is large. The entire classifica-
tion is described by under 40 classifiers.
4. Other tumor classifications divide tumors by medical
specialty (e.g. dermatologic neoplasms, hematologic neo-
plasms, thoracic neoplasms, etc.) This classification is
based on biologic principles. The classification uses a fea-
ture from developmental biology to capture the most
important genomic dichotomy in tumor biology, the sep-
aration of tumors with simple and characteristic genetic
abnormalities from tumors with genetic instability.
5. The classification has "competence." In the field of
informatics, competence is the ability to answer questions
related to the instances of a data group.
6. The classification is represented as an XML document.
7. It is easy to add subdivisions to the classification. This
is important, as the molecular analysis of tumors is likely
to provide new taxa.
8. It is easy to move subdivisions of the classification.
Classifications are hypothetical re-creations of reality and
must be changed as information is accrued.
9. The classification is easily understood by developmen-
tal biologists. Developmental biologists are major partici-
pants in post-genomic science and need to have tools to
relate basic research with clinical exigencies.
10. The classification is compatible with modern theories
of the "stem cell" origin of tumors.
11. The classification does not invalidate existing diag-
noses found in pathology reports. The medicolegal
importance of this feature cannot be exaggerated. This
relieves pathologists from reviewing all their prior cases
and re-diagnosing them in conformance with a new clas-
sification.
12. The classification is an open access document that can
be used or criticized freely by the biomedical community.
Discussion
In general, creating a coherent classification is an intellec-
tually demanding process. Aristotle was the first great clas-
sifier. Observing that dolphins have a placenta, he
reasoned that dolphins are mammals, not fish. This
insight was greeted with almost uniform derision for
nearly two thousand years. The fortunes of taxonomists
have barely improved in the interim. Gould complains
that taxonomy is portrayed as the dullest of all fields [14].
"But classifications are not passive ordering devices in a
world objectively divided into obvious categories. Taxon-
omies are human decisions imposed upon nature – theo-
ries about the causes of nature's order [14]. In a recent
letter to Nature, Thiele and Yeates comment that research
funds go into high profile projects (like the human
genome project) but miss classification projects [15].
Classification projects are never-ending because class
assignments are tentative and subject to continual testing
and improvement [16].
Upper level classification
The highest levels of the classification are the primitive
tumors (which include the teratomas and the primitive
blastic tumors), tumors of endoderm/ectoderm lineage
(containing the overwhelming majority of human can-
cers), tumors of mesodermal lineage (including all sarco-
mas) and tumors of neuroectodermal lineage.
The most important value of this classification is the dis-
engagement of tumor type and tumor place of origin. A
primitive blastoma may occur in the bone or the brain or
the lung, but it is classified along with the other primitive
blastomas regardless of location. This permits tumors
with similar molecular profiles to be classified according
to biological attributes rather than anatomic location (e.g.
Ewing's tumor family).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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The separation of endodermal/ectodermal from mesoder-
mal tumors is one of the most successful categorizations
in tumor biology. The sarcomas tend to have simple
cytogenetic and molecular markers (typically transloca-
tions leading to gene fusions) [17]. Ectodermal/endoder-
mal tumors tend to have complex cytogenetic
abnormalities and genetic instability [18]. The sarcomas
behave quite differently from endodermal/ectodermal
tumors. Sarcomas metastasize via the blood vessels, and
the endodermal/ectodermal tumors metastasize through
the lymphatics. The morphologies of the tumor classes are
different. Sarcomas tend to have a spindle cell appearance
while endodermal/ectodermal cells have an epithelial
appearance. It seems very likely that the functional molec-
ular pathways responsible for the malignant phenotype in
sarcomas will be different from the pathways followed for
endodermal/ectodermal tumors, and that this will result
in fundamentally different approaches to finding thera-
peutic targets against molecular pathways in these tumor
classes.
The current classification replaces the morphologic and
arbitrary dichotomy of epithelial and non-epithelial neo-
plasms with the histogenetically definitive concepts of
ectodermal/endodermal and non-ectodermal/endoder-
mal neoplasms. The class of ectodermal/endodermal
tumors contains most of the neoplasms that are morpho-
logically epithelial. However, a variety of epithelial
tumors derive from mesoderm (e.g., renal cell carcinoma,
adrenal cortical adenoma and papillary carcinomas of
ovary), or neuroectoderm (e.g. melanoma, medullary car-
cinoma of thyroid). It would seem that these mesodermal
and neuroectodermal epithelial tumors may display class
behavior independent of their epithelial morphology.
Lower level classification
The classification clarifies many of the genetic and molec-
ular oddities in the field of tumor biology. It distinguishes
endocrine tumors based on histogenesis, not by function.
Adrenal glands should be thought of as two different
glands (medulla and cortex) containing two endocrine
cell-types, each with its own embryonic lineage. The
medulla derives from neuroectoderm and is sometimes
associated with genetic syndromes that involve neuroec-
toderm-classed tumors. The best example is multiple
endocrine adenomatosis type 2a (MEN 2a), characterized
by the combined presence of pheochromocytoma and
medullary thyroid carcinoma. Both tumors have a neur-
oectodermal endocrine lineage, the former arising from
the adrenal medulla and the latter arising from neural
crest C-cells (calcitonin-producing cells) that migrate to
the thyroid gland. MEN2 is characterized by ret gene
mutations [19]. A variety of related genetic syndromes are
characterized by pheochromocytomas, medullary thyroid
tumors and other neural crest-derivative tumors and carry
the ret gene mutation [20,21].
The adrenal cortex is mesodermal in lineage and produces
adrenal cortical steroid producing cells, strikingly similar
to the steroid cell tumors derived from ovarian meso-
derm. The occurrence of adrenal cortical tumors in multi-
ple endocrine adenomatosis type 1 (MEN 1) is somewhat
anomalous because all the other endocrine tumors associ-
ated with this syndrome are of endoderm endocrine line-
age. These include pancreatic islet cell tumors, pituitary
tumors and parathyroid tumors. Recent evidence suggests
that the adrenal cortical adenomas occur secondarily in
response to ACTH hypersecretion and are genetically dis-
tinct from the endoderm-derived adenomas seen in
MEN1 [22].
Germ cell tumors, in the present classification, are placed
adjacent to, but separate from, the teratomas and embry-
onal carcinomas in a developmental stage prior to the
developmental of the embryonic layers (ectoderm, endo-
derm and mesoderm). This is a departure from classifica-
tions of ovarian tumors that include germ cell tumors and
ovarian teratomas in the same class. It is the author's opin-
ion that germ cells are different from totipotent embry-
onic cells. The pure germ cell tumors are seminomas and
dysgerminomas. When germ cell tumors are found mixed
with teratomas, one can infer a transformation between
the different cell types (i.e. germ cells giving rise to totipo-
tent embryonic cells or vice versa).
The ovary, in the current classification, has three anlagen:
germ cell, coelomic gonadal and sub_coelomic_gonadal.
The appendages of the ovary are derived from
coelomic_ducts (paramesonephric or mesonephric).
None of the ovary is derived from endoderm or ectoderm.
This explains the strangeness and the diversity of tumors
arising in, on, or adjacent to the ovary.
Mesotheliomas and synovial sarcomas are placed into the
class of tumors with mesodermal, coelomic cavity lineage.
This classification emphasizes their similar histogenesis
and similar morphology as biphasic epithelioid/spindle
tumors. Both tumors have similar histochemical features,
producing hyaluronic acid and chondroitin sulfate, the
lubricants of coelomic cavities [23]. These two tumors,
however, have different cytogenetic features. Synovial sar-
comas are characterized by syt-ssx fusion transcipts [24],
while mesotheliomas have complex cytogenetic abnor-
malities. It is interesting that synovial sarcomas can arise
from many different soft tissue locations, including peri-
cardium and pleura (coelomic cavities) [25-28]. This find-
ing suggests that mesotheliomas and synovial sarcomas
are closely related.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/10
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Renal tumors are separated from the class of ectodermal/
endodermal tumors. The histogenetic anlage for the kid-
ney is metanephric mesoderm. Renal tumors clearly
belong in a different class than endodermal/ectodermal
tumors. Interestingly, a subset of renal tumors is charac-
terized by fusion gene (PRCC to the TFE3 transcription
factor gene). Fusion gene neoplasia is a characteristic
absent from tumors of ectodermal/endodermal lineage.
The histogenesis of uterine tumors has always presented a
special intellectual challenge [29]. This classification of
the uterine tumors offers a radical departure from the clas-
sic separation of tumors into epithelial and mesenchymal
origins. The uterus, like the kidney, has a purely mesoder-
mal lineage, with no contribution from endoderm or
ectoderm (the common lineage for mucosal lining cells).
Specifically, the uterus is formed from a duct that forms
within the mesoderm (the paramesonephric duct). This
duct gives rise to the endometrial epithelium as well as the
underlying stroma. Consequently, tumors of endometrial
and stromal cells share the same classification (sub-coe-
lomic ductal). Like the kidney, this classification ignores
morphologic differences (epithelial versus mesenchymal)
and creates a grouping in concordance with the observed
mixed epithelial/stromal manifestations of some uterine
tumors.
Unresolved issues
The largest class of tumors falls into the ectoderm/endo-
derm class. This class includes the leading causes of death
in man (bronchogenic carcinoma, colon adenocarci-
noma, breast carcinoma and prostate carcinoma and the
most frequently occurring (though usually non-lethal)
tumors of man (squamous cell carcinoma of skin and
basal cell carcinoma of skin). Because so many lesions fall
into this one category, it might seem that the classification
lacks sufficient complexity.
The human body can be envisioned as a topological
donut. It is covered by lining cells, with the donut hole
lined by endoderm and the donut outer surface lined by
ectoderm. The donut pastry would be the mesoderm. Vir-
tually all exposure to toxic and carcinogenic chemicals is
via the surface (ectodermal skin or donut surface) or
through our aero-digestive tract (endodermally derived
lungs and alimentary tract or donut hole-lining cells).
Since ectoderm and endoderm are the cells that are most
exposed to carcinogens, it's not surprising that most
human cancer falls under the class of ectodermal/endo-
dermal tumors. Likewise, since exposure via the ecto-
derm/endoderm is a lifelong process, it is not surprising
that ectodermal/endodermal tumors tend to increase in
incidence with age, occurring disproportionately among
the elderly. If further research reveals new taxa that can
usefully separate tumors of endodermal and ectodermal
lineage, the current classification would accommodate the
change. The combined endodermal/ectodermal class
would remain intact because tumors of either lineage have
features in common that distinguish them from mesoder-
mal or primitive tumors. Each member of the class of
endodermal/ectodermal tumors would be assigned a spe-
cific subclass.
How do we know if the classification is correct? The cor-
rectness of a classification is determined by adding new
feature information that characterize classes and
instances. When newly added group features extend
beyond the class or fail to extend to descendant classes or
fail to extend to all the members of a class, the classifica-
tion needs to be modified. Testing the classification is a
never-ending but worthwhile process.
Mayr equates classifications with macrotaxonomies [3].
The taxonomy is the list of objects included in the macro-
taxonomy. The macro-taxonomy is the scaffold into
which the members of the taxonomy might fit. Provided
with this article is a "filled-in" classification, using approx-
imately 55,000 neoplasia terms extracted from the NCI-
Thesaurus [see Additional file 2].
Summary
A tumor classification is proposed that groups each tumor
according to embryonic lineage. This classification is pre-
pared as an XML file designed to accommodate additional
attributes (e.g. genomic, proteomic, clinical information).
The classification is comprehensive (can include all neo-
plastic entities) and parsimonious (each entity has one
lineage). This classification blends traditional concepts of
tumor nomenclature with post-genomic concepts of neo-
plastic development. The classification structure and the
classification with taxonomic annotation (approximately
55,000 terms) are available as supplemental files with this
article.
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Neoplasia classification structure (XML version). Neoclass.xml is a pure 
XML file that can be viewed in current web browsers. It shows the bare 
classification scheme, with a few sample annotations. The file must have 
a .xml filename suffix before it can be opened and viewed on a web 
browser. If this suffix is lost during download, the reader should simply 
rename the file neoclass.xml to provide the .xml suffix.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-10-S1.xml]
Additional File 2
Neoplasia classification with taxonomy (XML version). Neoclxml.gz is a 
compressed (gzipped) pure XML file. If the filename is changed during 
download, it should be renamed neoclxml.gz so that the .gz suffix can be 
recognized by unzip utilities. Unzip the file (recommended utility: gun-
zip.exe). Once unzipped, the file is 4 Mbytes in length. The expanded file 
should be renamed neocl.xml, to provide an XML suffix recognizable to 
web browsers. It can be opened on current versions of popular web brows-
ers, but because it is a very large file, it may require substantial memory 
to view. The file contains approximately 55,000 coded neoplasia terms, all 
assigned to the classification structure.
Click here for GZ version of file
Click here for ZIP version of file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-10-S2.gz]